Biodesix Strengthens Its Partnership with Bio-Rad for Advanced Diagnostics
Biodesix Expands Partnership with Bio-Rad Laboratories
Biodesix, Inc. (NYSE: BDSX), a pioneering name in diagnostics solutions, is set to enhance its offerings significantly through a new partnership agreement with Bio-Rad Laboratories. This strategic collaboration focuses on developing in vitro diagnostic (IVD) assays that leverage the advanced capabilities of Bio-Rad's Droplet Digital™ PCR (ddPCR™) technology.
Innovative Technologies for Oncology Applications
The initial focus under this expanded agreement will be the development of assays aimed at the early and sensitive detection of genomic markers in oncology. One of the key assays to be validated is Bio-Rad's ddPLEX ESR1 Mutation Detection Assay. This particular test is becoming increasingly crucial in the assessment of HR+/HER2- advanced breast cancer patients, especially in light of the groundbreaking benefits offered by new oral therapies known as selective estrogen receptor degraders (SERDs).
Clinical Validation and Patient Outcomes
Once the ESR1 assay undergoes clinical validation, it will be readily available to both biopharma clients for therapeutic advancements and clinical customers for ongoing cancer treatment monitoring. A significant goal for Biodesix is to seek reimbursement for this assay through the Centers for Medicare & Medicaid Services (CMS), which would enhance accessibility for patients requiring detailed genomic insights.
Leadership Insights on Partnership Impact
Scott Hutton, CEO of Biodesix, expressed his excitement regarding the partnership, stating, "The emergence of ESR1 mutations as biomarkers for breast cancer has had a significant impact on the oncology market, leading to an increased global demand for rapid, sensitive assays." He highlighted how this alliance not only bolsters their operating capability but also opens new avenues for personalized, data-driven medicine.
Long-Standing Relationship Yielding Results
Steve Kulisch, VP of Product Management at Bio-Rad Laboratories, noted that their ongoing relationship has been fruitful in delivering effective clinical applications of ddPCR technology, especially in non-small cell lung cancer diagnostics. He emphasized that further validation of the ddPLEX ESR1 kits will expand both companies' contributions to clinical diagnostics and increase access to vital biomarker detection.
Upcoming Events and Knowledge Sharing
At the upcoming AMP conference, significant opportunities will arise for Biodesix and Bio-Rad to present their respective research and development visions and commercial strategies. Attendees can look forward to detailed insights during their corporate workshops scheduled on November 12.
- Bio-Rad Laboratories Corporate Workshop, Nov 12, at 8:00 am ET
- Biodesix Corporate Workshop, Nov 12, at 4:00 pm ET
About Biodesix and Its Impact on Diagnostics
Biodesix's mission is to enhance clinical care and patient outcomes through innovative diagnostic solutions. Their diagnostic tests, such as Nodify Lung® for nodule risk assessment and IQLung® for cancer treatment guidance, exemplify their commitment to facilitating personalized medical care. Through these developments, Biodesix is equipped to provide essential capabilities that support the advancement of diagnostic tests and therapeutics in the life sciences sector.
Contacting Biodesix
For further information, individuals may reach out to the company’s contacts:
Media Inquiries:
Natalie St. Denis, Director of Corporate Communications
Email: natalie.stdenis@biodesix.com
Phone: (720) 925-9285
Investor Relations:
Chris Brinzey, Partner, ICR
Email: chris.brinzey@icrhealthcare.com
Phone: (339) 970-2843
Frequently Asked Questions
What is the purpose of the collaboration between Biodesix and Bio-Rad?
The collaboration aims to develop highly sensitive IVD assays for oncology applications using Bio-Rad's advanced PCR technology.
What is the significance of the ESR1 Mutation Detection Assay?
This assay enables sensitive detection and quantification of ESR1 mutations, which are vital in treating advanced breast cancer.
Where will the ESR1 assay be available?
Once validated, the ESR1 assay will be offered at Biodesix' accredited CLIA-CAP laboratory for various clinical and biopharma customers.
How will the partnership benefit patients?
The collaboration will enhance access to precise diagnostics, ultimately improving patient care and treatment outcomes in oncology.
What upcoming events will showcase this partnership's innovations?
Biodesix and Bio-Rad will present at the AMP conference, offering details on their R&D initiatives and commercial plans.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.